Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Don W. Kassing sold 170 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $223.18, for a total value of $37,940.60. Following the completion of the sale, the director now directly owns 1,175 shares of the company's stock, valued at $262,236.50. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Penumbra Price Performance
Penumbra stock opened at $215.17 on Thursday. Penumbra, Inc. has a 12 month low of $180.93 and a 12 month high of $348.67. The company has a current ratio of 6.06, a quick ratio of 3.49 and a debt-to-equity ratio of 0.02. The business's 50 day simple moving average is $245.42 and its 200 day simple moving average is $235.46. The company has a market cap of $8.33 billion, a price-to-earnings ratio of 93.15, a PEG ratio of 2.09 and a beta of 0.51.
Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.71 by $0.05. Penumbra had a return on equity of 7.49% and a net margin of 8.59%. The business had revenue of $284.68 million for the quarter, compared to the consensus estimate of $286.62 million. During the same quarter in the prior year, the business earned $0.16 earnings per share. Penumbra's revenue for the quarter was up 28.7% on a year-over-year basis. Sell-side analysts forecast that Penumbra, Inc. will post 2.85 EPS for the current year.
Institutional Investors Weigh In On Penumbra
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
From Colonial Metals | Ad
The latest flare-up between Israel and Palestinian militants has sent gold prices surging.
Why? Because savvy investors know the endgame of the elites at play…
Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
See why the elites are pouring billions into gold.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Penumbra by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,658,103 shares of the company's stock worth $920,159,000 after purchasing an additional 58,184 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Penumbra by 58.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,104,590 shares of the company's stock worth $780,930,000 after buying an additional 1,140,807 shares in the last quarter. Finally, State Street Corp raised its position in shares of Penumbra by 1.5% in the second quarter. State Street Corp now owns 1,061,701 shares of the company's stock worth $365,289,000 after buying an additional 16,028 shares in the last quarter. Institutional investors own 88.88% of the company's stock.
Analyst Ratings Changes
PEN has been the subject of a number of analyst reports. Royal Bank of Canada reiterated an "outperform" rating and set a $289.00 price target on shares of Penumbra in a research note on Friday, February 23rd. Piper Sandler reiterated an "overweight" rating and set a $290.00 price target on shares of Penumbra in a research note on Wednesday. TheStreet upgraded Penumbra from a "d+" rating to a "c-" rating in a research note on Friday, January 12th. Truist Financial cut their price target on Penumbra from $290.00 to $280.00 and set a "buy" rating for the company in a research note on Friday, March 22nd. Finally, JPMorgan Chase & Co. downgraded Penumbra from an "overweight" rating to a "neutral" rating and cut their price target for the company from $284.00 to $250.00 in a research note on Friday, February 23rd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $304.45.
Check Out Our Latest Stock Report on Penumbra
About Penumbra
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
